{
    "xml": "<topic id=\"PHP5467\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/eribulin\" basename=\"eribulin\" title=\"ERIBULIN\">\n<title>ERIBULIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1205\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/eribulin\">Eribulin</xref>\n</p>\n<data name=\"vtmid\">18773111000001108</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_331992203\" title=\"Halichondrin derivatives\">Halichondrin derivatives</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP70415\" outputclass=\"indicationsAndDose\" rev=\"1.27\" parent=\"/drugs/eribulin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of locally advanced or metastatic breast cancer when the disease has progressed after treatment with at least 1 chemotherapy regimen for advanced disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Give on day 1 and day 8 of a 21-day cycle, previous therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless the patient is unsuitable for these treatments (consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70458\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/eribulin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Congenital long QT syndrome</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70470\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/eribulin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Bradyarrhythmias (increased susceptibility to QT-interval prolongation)</ph>; <ph outputclass=\"caution\">congestive heart failure (increased susceptibility to QT-interval prolongation)</ph>; <ph outputclass=\"caution\">electrolyte disturbances (increased susceptibility to QT-interval prolongation)</ph>; <ph outputclass=\"caution\">susceptibility to QT-interval prolongation</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70406\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/eribulin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (eribulin).</p>\n<p>Caution with concomitant use of drugs that prolong QT-interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70355\" outputclass=\"sideEffects\" rev=\"1.17\" parent=\"/drugs/eribulin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">myelosuppression</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">QT-interval prolongation</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For further information on side effects, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70463\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/eribulin\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;ensure effective contraception during and for up to 3 months after treatment in men or women.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70395\" outputclass=\"pregnancy\" parent=\"/drugs/eribulin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Avoid unless essential (teratogenic in <i>animal </i>studies).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70480\" outputclass=\"breastFeeding\" parent=\"/drugs/eribulin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70429\" outputclass=\"hepaticImpairment\" parent=\"/drugs/eribulin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70377\" outputclass=\"renalImpairment\" parent=\"/drugs/eribulin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Consider dose reduction if creatinine clearance less than 40&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70304\" outputclass=\"monitoringRequirements\" parent=\"/drugs/eribulin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for signs of peripheral neuropathy&#8212;severe peripheral neurotoxicity requires treatment delay or dose reduction (consult product literature).</p>\n<p>ECG monitoring recommended in patients prescribed concomitant use of drugs that prolong the QT-interval or who are susceptible to QT-interval prolongation.</p>\n<p>Monitor electrolytes periodically.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70263\" outputclass=\"nationalFunding\" rev=\"1.15\" parent=\"/drugs/eribulin\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA250</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Eribulin for the treatment of locally advanced or metastatic breast cancer (April 2012)</p>\r\n<p>Eribulin is <b>not</b> recommended for the treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA250\">www.nice.org.uk/TA250</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5467-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/eribulin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75812\" title=\"Solution for injection\" namespace=\"/drugs/eribulin/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1205\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/eribulin\" title=\"Eribulin\" count=\"1\" rel=\"link\">Eribulin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75812\" namespace=\"/drugs/eribulin/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5467",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/eribulin",
    "basename": "eribulin",
    "title": "ERIBULIN",
    "interactants": [
        {
            "id": "bnf_int_1205",
            "label": "Eribulin"
        }
    ],
    "vtmid": "18773111000001108",
    "drugClassification": [
        "Halichondrin derivatives"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of locally advanced or metastatic breast cancer when the disease has progressed after treatment with at least 1 chemotherapy regimen for advanced disease",
                        "html": "Treatment of locally advanced or metastatic breast cancer when the disease has progressed after treatment with at least 1 chemotherapy regimen for advanced disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Give on day 1 and day 8 of a 21-day cycle, previous therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless the patient is unsuitable for these treatments (consult local protocol).",
                        "html": "<p>Give on day 1 and day 8 of a 21-day cycle, previous therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless the patient is unsuitable for these treatments (consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Congenital long QT syndrome",
                "html": "Congenital long QT syndrome"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Bradyarrhythmias (increased susceptibility to QT-interval prolongation)",
                "html": "Bradyarrhythmias (increased susceptibility to QT-interval prolongation)"
            },
            {
                "type": "cautions",
                "textContent": "congestive heart failure (increased susceptibility to QT-interval prolongation)",
                "html": "congestive heart failure (increased susceptibility to QT-interval prolongation)"
            },
            {
                "type": "cautions",
                "textContent": "electrolyte disturbances (increased susceptibility to QT-interval prolongation)",
                "html": "electrolyte disturbances (increased susceptibility to QT-interval prolongation)"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to QT-interval prolongation",
                "html": "susceptibility to QT-interval prolongation"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (eribulin).\n\nCaution with concomitant use of drugs that prolong QT-interval.",
                "html": "<p>Appendix 1 (eribulin).</p><p>Caution with concomitant use of drugs that prolong QT-interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression",
                        "html": "myelosuppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "QT-interval prolongation",
                        "html": "QT-interval prolongation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "For further information on side effects, consult product literature.",
                "html": "<p>For further information on side effects, consult product literature.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;ensure effective contraception during and for up to 3 months after treatment in men or women.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212;ensure effective contraception during and for up to 3 months after treatment in men or women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Avoid unless essential (teratogenic in animal studies).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.",
                "html": "<p>Avoid unless essential (teratogenic in <i>animal </i>studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose.",
                "html": "<p>Reduce dose.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Consider dose reduction if creatinine clearance less than 40 mL/minute.",
                "html": "<p>Consider dose reduction if creatinine clearance less than 40&#8239;mL/minute.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for signs of peripheral neuropathy&#8212;severe peripheral neurotoxicity requires treatment delay or dose reduction (consult product literature).\n\nECG monitoring recommended in patients prescribed concomitant use of drugs that prolong the QT-interval or who are susceptible to QT-interval prolongation.\n\nMonitor electrolytes periodically.",
                "html": "<p>Monitor for signs of peripheral neuropathy&#8212;severe peripheral neurotoxicity requires treatment delay or dose reduction (consult product literature).</p><p>ECG monitoring recommended in patients prescribed concomitant use of drugs that prolong the QT-interval or who are susceptible to QT-interval prolongation.</p><p>Monitor electrolytes periodically.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA250",
                        "label": "www.nice.org.uk/TA250"
                    }
                ],
                "fundingIdentifier": "NICE TA250",
                "textContent": "Eribulin for the treatment of locally advanced or metastatic breast cancer (April 2012) Eribulin is not recommended for the treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease.\n\nwww.nice.org.uk/TA250",
                "html": "<p outputclass=\"title\">Eribulin for the treatment of locally advanced or metastatic breast cancer (April 2012)</p> <p>Eribulin is <b>not</b> recommended for the treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA250\">www.nice.org.uk/TA250</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75812",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1205",
                "label": "Eribulin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75812",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}